The Cooper Companies(COO) - 2025 Q4 - Annual Results

Revenue Performance - Fourth quarter 2025 revenue reached $1,065.2 million, a 5% increase year-over-year, with organic growth of 3%[3] - Fiscal year 2025 revenue totaled $4.1 billion, up 5% from fiscal 2024, with organic growth of 4%[11] - Fiscal first quarter 2026 revenue guidance is set between $1,019 million and $1,030 million, with organic growth projected at 3% to 4%[13] - Fiscal 2026 total revenue guidance is between $4,299 million and $4,338 million, with organic growth of 4.5% to 5.5%[13] - Total net sales for the three months ended October 31, 2025, were $1,065.2 million, representing a 5% year-over-year increase from $1,018.4 million in the same period of 2024[49] - CooperVision's net sales for the fourth quarter of 2025 were $709.6 million, with an organic growth rate of 3%[51] - CooperSurgical's net sales for the fourth quarter of 2025 were $355.6 million, also reflecting an organic growth rate of 4%[51] Earnings and Profitability - Fourth quarter 2025 non-GAAP diluted EPS was $1.15, an 11% increase year-over-year, while GAAP diluted EPS was $0.43, down 27%[3] - GAAP net income for the three months ended October 31, 2025, was $84.6 million, with an EPS of $0.43, compared to $117.5 million and $0.58 EPS for the same period in 2024, representing a decrease of 28.0% in net income[25] - Non-GAAP net income for the twelve months ended October 31, 2025, was $826.5 million, with an EPS of $4.13, compared to $740.5 million and $3.69 EPS for the same period in 2024, indicating an increase of 11.6% in net income[25] - The company reported a net income of $374.9 million for the year ended October 31, 2025, down from $392.3 million in 2024, a decrease of about 4.3%[49] - Diluted earnings per share for the year ended October 31, 2025, were $1.87, compared to $1.96 in 2024, representing a decline of approximately 4.6%[49] - Gross profit for the year ended October 31, 2025, was $2,682.1 million, up from $2,595.7 million in 2024, indicating a growth of approximately 3.4%[49] Share Repurchase and Cash Flow - The company repurchased $197.3 million of common stock in Q4 2025, with a total of $290.1 million repurchased for the fiscal year[13] - The Board of Directors expanded the share repurchase program by $1 billion, bringing total authorization to $2 billion[13] - The company expects free cash flow to exceed $2.2 billion from 2026 to 2028, supporting share repurchases and strategic investments[2] Charges and Expenses - Total charges related to acquisition and integration for the three months ended October 31, 2025, amounted to $15.7 million, compared to $7.2 million in the same period of 2024, reflecting a 118.1% increase[25] - The company incurred $24.6 million in exit of business charges for the three months ended October 31, 2025, while no such charges were recorded in the same period of 2024[25] - The company reported a total of $451.6 million in total charges for the twelve months ended October 31, 2025, compared to $348.2 million in 2024, marking a 29.7% increase[25] - Research and development expenses for the year ended October 31, 2025, totaled $172.2 million, compared to $155.1 million in 2024, reflecting an increase of 11%[49] Market Presence and Future Outlook - The company is focused on expanding its market presence through acquisitions, specifically mentioning the obp Surgical and Cook Medical integration efforts[28] - Future guidance for fiscal year 2026 includes anticipated growth in revenues and expected savings from ongoing reorganization activities[40] - The company has a workforce of over 15,000 and sells products in over 130 countries, positively impacting over fifty million lives each year[39] Balance Sheet - Total assets as of October 31, 2025, were $12,394.8 million, a slight increase from $12,315.2 million as of October 31, 2024[47] - Total liabilities decreased to $4,155.7 million as of October 31, 2025, from $4,231.6 million in 2024, a reduction of about 1.8%[47] Other Considerations - The company emphasized the importance of ongoing research and development activities and the potential impact of environmental regulations on future operations[43]